Last March 25-28, 2026, the European Lung Cancer Congress (ELCC) 2026 was held in Copenhagen, Denmark. David Burger presented a poster titled “Patient attitudes towards an expert-based website to screen for drug-drug interactions between lung cancer agents and co-medications“.

The Lung Cancer DDI Manager was evaluated by members of the ALK Positive Inc. Facebook support group, an American patient association for people with ALK-positive lung cancer.

Although the tool was originally developed for healthcare professionals, patients demonstrated a comparable ability to use it effectively. Notably, 72% of respondents indicated that the tool would help them discuss potential DDIs with their healthcare providers.

These findings highlight that patients can be successfully empowered to use an expert-based DDI tool to gain insight into potential interactions and to actively engage in shared decision-making.

Interested in exploring potential drug-drug interactions for lung cancer treatments? Visit our Lung Cancer DDI Manager to access this expert-based tool.